The Foreign Corrupt Practices Act: Risk-Management and Compliance Strategies For Life Sciences and Pharmaceutical Companies
October 16, 2009
Just past its 30th birthday, the Foreign Corrupt Practices Act of 1977 (the FCPA or the Act) today poses the greatest liability risks ever for U.S. firms and other covered entities pursuing business opportunities abroad. Chiefly, this risk arises due to the increased risk of prosecution by the U.S. government, the government’s increased appetite for large fines, and an increased risk of multiple prosecutions due to other countries having adopted FCPA-equivalent laws.
Read the complete article by clicking on the link below.
Author(s)
Related Insights
April 16, 2026
Manufacturing Industry Advisor
Foley Automotive Update
Foley is here to help you through all aspects of rethinking your long-term business strategies, investments, partnerships, and technology. Contact the authors, your Foley relationship partner, or our Automotive Team to discuss and learn more.
April 16, 2026
Foley Viewpoints
USPTO's AI Search Pilot May Reshape Patent Filing Strategy
The U.S. Patent and Trademark Office's Artificial Intelligence Search Automated Pilot, or ASAP, program introduces earlier visibility into the prior art landscape by providing applicants with an automated search results notice prior to substantive examination.
April 16, 2026
Foley Viewpoints
Delaware Chancery Rejects “Race to the Courthouse” in Enforcing Texas Exclusive Forum Bylaw, Dismissing Three Derivative Lawsuits filed before Tesla’s Redomestication
On April 13, 2026, the Delaware Court of Chancery dismissed three derivative suits in In re Tesla, Inc. Derivative Litigation based on Tesla’s forum selection bylaw requiring that those lawsuits be brought in Texas. All three derivative lawsuits were filed after Tesla announced its proposal to redomesticate and adopt a Texas exclusive forum bylaw but before the redomestication and amended bylaw became effective after shareholder approval.